Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · Pharmaceutical Preparations · Silver Spring, MD

Our rating: Positive

Positive reaffirmed at $565.72, moderate conviction, November 5, 2026.

Breaks if: The Positive call weakens if reported revenue growth decelerates below 5% year-over-year for two consecutive quarterly prints — a signal that the Tyvaso DPI ramp is flattening materially earlier than the current trajectory implies — or if free cash flow margin drops below 20% (against the current ~31%) across the next two quarterly reports, indicating that capital spending has moved from strategically justified to structurally dilutive. On the other side, two consecutive quarters of revenue growth above 15% combined with FCF margin recovering toward 35% would prompt a re-evaluation toward Conviction.

Key figures

Market value$23.6B
Revenue, last 12 months$3.2B
Net income, last 12 months$1.2B
Free cash flow, last 12 months$867M
Price to earnings19.2×
Free cash flow yield3.7%
Dividend yield0.0%
Operating margin41.4%
Return on equity19.1%
Beta to the S&P 5000.43
Volatility, annualized40.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$833M4.1%$5.71$126M
June 30, 2026$783M−1.9%$7.27$206M
March 31, 2026$782M−1.6%$5.82$363M
December 31, 2025$790M7.4%$7.69$173M
September 30, 2025$800M6.8%$7.16$352M
June 30, 2025$799M11.7%$6.41$130M
March 31, 2025$794M17.2%$6.63$386M
December 31, 2024$736M19.7%$6.21$255M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

11 ledger entries and 13 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.